Pioneering diagnostics
E.g., 14/10/2019
E.g., 14/10/2019

First-Half 2019 Results

04 September, 2019

bioMérieux – First-Half 2019 Results


  • Organic sales growth of 5.5% for first-half 2019:
    • €1,275 million in sales
    • Up 9.1% as reported
  • As expected...

bioMérieux increases its holding in Hybiome from 54% to 67%

06 June, 2019

bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier announcement of the acquisition of a majority stake in this...

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for Perioperative Care in Cardiac Surgery”

13 May, 2019

The NEPHROCHECK® Test biomarkers (TIMP-2 and IGFBP7) that indicate kidney stress in advance of acute kidney injury (AKI) have been included in the “Guidelines for Perioperative Care in Cardiac Surgery” which were published by the ERAS® (Enhanced Recovery After...

bioMérieux – First-Quarter 2019 Business Review

24 April, 2019

  • Organic growth of 3.8% (at constant exchange rates and scope of consolidation)

    • €632 million in sales

    • Up 7.7% as...

“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients  

15 April, 2019

 bioMérieux, a world leader in the field of in vitro diagnostics, and the Laboratory of Medical Microbiology at the University of Antwerp announced at ECCMID (European Congress of Clinical Microbiology & Infectious Diseases) the 2018 results of the Global Point...

University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics

02 April, 2019

Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 - The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitro...

Baxter and bioMérieux announce collaboration to improve identification and treatment of acute kidney injury

19 March, 2019

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux, a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). The...

bioMérieux – 2018 Financial Results

27 February, 2019

  • Organic sales growth of 9.9% for full-year 2018:
    • €2,421 million in sales
    • Up 5.8% as reported
    • Solid fourth-quarter performance, with organic growth of more than 10%
  • Improvement in...

bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing

07 February, 2019


bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and...

bioMérieux receives FDA clearance for BPA and BPN culture bottles used with BACT/ALERT® VIRTUO® for quality control testing of platelets

19 December, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-...